首页> 外国专利> New non-naturally occurring variant of glutaryl amidase comprising histidine or glutamate in its substrate binding pocket, binds cephalosporin C (CPC) as substrate and catalyzes conversion of CPC to 7-aminocephalosporanic acid

New non-naturally occurring variant of glutaryl amidase comprising histidine or glutamate in its substrate binding pocket, binds cephalosporin C (CPC) as substrate and catalyzes conversion of CPC to 7-aminocephalosporanic acid

机译:新的非天然存在的戊二酰酰胺酶变体,在其底物结合口袋中包含组氨酸或谷氨酸,结合头孢菌素C(CPC)作为底物并催化CPC转化为7-氨基头孢烷酸

摘要

Non-naturally occurring variant of a glutaryl amidase (GA) (I) which binds cephalosporin C (CPC) as a substrate and catalyzes conversion of the CPC to 7-aminocephalosporanic acid (7-ACA), where the variant comprises a histidine or glutamate in the substrate binding pocket that binds the alpha -amino adipyl moiety of the CPC, is new. A non-naturally occurring variant of a glutaryl amidase (GA) (I) which binds cephalosporin C (CPC) as a substrate and catalyzes conversion of the CPC to 7-aminocephalosporanic acid (7-ACA), where the variant comprises a histidine or glutamate in the substrate binding pocket that binds the alpha -amino adipyl moiety of the CPC. (I) comprises a combination of mutations chosen from PheB177His, LeuB24Arg, ArgB57His; PheB177His, LeuB24Arg, ArgB57His, GlnB50Val; PheB177His, LeuB24Arg, ArgB57His, GlnB50Ala; PheB177His, LeuB24Arg, ArgB57His, GlnB50Val, ValB70His; PheB177His, LeuB24Arg, ArgB57His, GlnB50Ala, ValB70His; PheB177His, LeuB24Arg, ArgB57His, GlnB50Val, ValB70His, TyrB153Leu; PheB177His, LeuB24Arg, ArgB57His, GlnB50Ala, ValB70His, TyrB153Leu; PheB177His, ThrB176Asp; PheB177His, ThrB176Asp, TyrA150Ala; PheB177His, ThrB176Asp, LeuB24Arg, ArgB57His; PheB177His, ThrB176Asp, LeuB24Arg, ArgB57His, TyrA150Ala; PheB177His, ThrB176Asp, GlnB50Arg, ArgB57His; PheB177His, ThrB176Asp, GlnB50Arg, ArgB57His, TyrA150Ala; TyrA150Glu; TyrA150Glu, PheB177His; TyrA150Glu, LeuB24Arg, ArgB57His; TyrA150Glu, LeuB24Arg, ArgB57His, PheB177His; TyrA150Glu, GlnB50Arg, ArgB57His; TyrA150Glu, GlnB50Arg, ArgB57His, PheB177His; PheB177His, ThrB176Asp, TyrA150Ala, TyrB33Ser; PheB177His, ThrB176Asp, LeuB24Arg, ArgB57His, TyrA150Ala, TyrB33Ser; PheB177His, ThrB176Asp, GlnB50Arg, ArgB57His, TyrA150Ala, TyrB33Ser; TyrA150Glu, PheB177His, TyrB33Ser; TyrA150Glu, LeuB24Arg, ArgB57His, TyrB33Ser; PheB177His, LeuB24Arg, ArgB57His, TyrB33Ser; and PheB177His, LeuB24Arg, ArgB57His, TyrB33Ser, ValB70His. Independent claims are also included for: (1) a polynucleotide (II) encoding (I); (2) a nucleic acid vector (III) comprising (II); (3) a host cell (IV) comprising (II) operably linked to regulatory control sequence which direct expression of the variant GA in the host cell; (4) production of (I); (5) production of 7-aminocephalosporanic acid; and (6) modifying (M1) a GA enzyme to enhance the CPC acylase activity of the enzyme, which involves by introducing a non-naturally occurring histidine or glutamate amino acid residue in the substrate binding pocket of the enzyme which histidine or glutamate binds the alpha -amino adipyl moiety of a CPC substrate molecule.
机译:谷氨酰胺酰胺酶(GA)(I)的非天然存在变体,它结合头孢菌素C(CPC)作为底物并催化CPC转化为7-氨基头孢菌酸(7-ACA),其中该变体包含组氨酸或谷氨酸结合CPC的α-氨基己二酰基部分的底物结合袋中的“新”。谷氨酰胺酰胺酶(GA)(I)的一种非天然存在的变体,它结合头孢菌素C(CPC)作为底物并催化CPC转化为7-氨基头孢烷酸(7-ACA),其中该变体包含组氨酸或底物结合袋中的谷氨酸结合CPC的α-氨基己二酰基部分。 (I)包含选自PheB177His,LeuB24Arg,ArgB57His的突变的组合; PheB177His,LeuB24Arg,ArgB57His,GlnB50Val; PheB177His,LeuB24Arg,ArgB57His,GlnB50Ala; PheB177His,LeuB24Arg,ArgB57His,GlnB50Val,ValB70His; PheB177His,LeuB24Arg,ArgB57His,GlnB50Ala,ValB70His; PheB177His,LeuB24Arg,ArgB57His,GlnB50Val,ValB70His,TyrB153Leu; PheB177His,LeuB24Arg,ArgB57His,GlnB50Ala,ValB70His,TyrB153Leu; PheB177His,ThrB176Asp; PheB177His,ThrB176Asp,TyrA150Ala; PheB177His,ThrB176Asp,LeuB24Arg,ArgB57His; PheB177His,ThrB176Asp,LeuB24Arg,ArgB57His,TyrA150Ala; PheB177His,ThrB176Asp,GlnB50Arg,ArgB57His; PheB177His,ThrB176Asp,GlnB50Arg,ArgB57His,TyrA150Ala; TyrA150Glu; TyrA150Glu,PheB177His; TyrA150Glu,LeuB24Arg,ArgB57His; TyrA150Glu,LeuB24Arg,ArgB57His,PheB177His; TyrA150Glu,GlnB50Arg,ArgB57His; TyrA150Glu,GlnB50Arg,ArgB57His,PheB177His; PheB177His,ThrB176Asp,TyrA150Ala,TyrB33Ser; PheB177His,ThrB176Asp,LeuB24Arg,ArgB57His,TyrA150Ala,TyrB33Ser; PheB177His,ThrB176Asp,GlnB50Arg,ArgB57His,TyrA150Ala,TyrB33Ser; TyrA150Glu,PheB177His,TyrB33Ser; TyrA150Glu,LeuB24Arg,ArgB57His,TyrB33Ser; PheB177His,LeuB24Arg,ArgB57His,TyrB33Ser;和PheB177His,LeuB24Arg,ArgB57His,TyrB33Ser和ValB70His。还包括以下方面的独立权利要求:(1)编码(I)的多核苷酸(II); (2)包含(II)的核酸载体(III)。 (3)一种宿主细胞(IV),其包含可操作地连接至调节变异序列GA在宿主细胞中表达的调节控制序列的(II); (4)生产(I); (5)生产7-氨基头孢烷酸; (6)修饰(M1)GA酶以增强该酶的CPC酰基转移酶活性,这涉及通过在该酶的底物结合口袋中引入非天然存在的组氨酸或谷氨酸氨基酸残基,该组氨酸或谷氨酸结合该氨基酸。 CPC底物分子的α-氨基己二酰基部分。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号